We’re delighted to announce that the first patients in the Midlands have now been treated using Sonablate HIFU, marking a major step forward in minimally invasive, precision-guided prostate cancer treatment.

Congratulations to the team at Northampton General Hospital NHS Trust for delivering this breakthrough – offering patients an advanced, tissue-sparing option with faster recovery and excellent outcomes.

Sonablate is the HIFU system of choice in active use across the NHS, backed by more than 15 years of NHS-generated clinical data. It is the trusted technology for prostate cancer focal therapy in the NHS, with a proven track record of safety, accuracy, and patient benefit.

Not all HIFU is the same. Sonablate stands apart in clinical validation, flexibility, and real-world NHS experience.

As the Master Distributor for Sonablate Corp in the UK Cerno Health is proud to support NHS centres in delivering the future of prostate cancer treatment.

We look forward to announcing new centres offering the world-leading Sonablate Corp. technology in the coming months!

Interested in starting or expanding a focal therapy program at your centre?
Contact Cerno Health today and join the growing number of NHS & Private hospitals transforming prostate cancer care across the UK.